# VetDC

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vetdc

- Industry: Healthcare Specialists
- Headquarters: Fort Collins, US
- Website: www.vet-dc.com
- Total disclosed funding: $2.5M
- Latest round: Series A (Nov 24, 2014)
- Investors on record: 1

## About

VetDC is a veterinary biotechnology company specializing in developing innovative cancer treatments for pets, focusing on improving the life quality of dogs diagnosed with lymphoma and other advanced cancers.Founded in 2009 and headquartered in Fort Collins, US, VetDC is dedicated to advancing veterinary oncology. The company has undergone no significant strategic pivots and has no known parent or subsidiary relationships. CEO Steven Roy leads the firm, which was co-founded by Terry Opgenorth. VetDC raised USD 2.5 million in Series A funding from High Country Venture and angel investors on November 24, 2014, marking its second deal and total funding raised at USD 2.5 million.VetDC specializes in developing innovative cancer treatments for pets, primarily focusing on canine lymphoma and other advanced cancer therapies. The company's core product, TANOVEA® (rabacfosadine for injection), effectively targets lymphoma in dogs, offering veterinarians an efficient treatment option. This product is the result of extensive evidence-based medical research aimed at translating human medical innovations into veterinary solutions. VetDC's client base includes veterinary oncologists, pet clinics, and animal hospitals across the United States, Canada, and selected regions in Europe, where the demand for advanced veterinary oncology solutions continues to grow.VetDC primarily generates revenue through B2B transactions with veterinary clinics and animal health distributors. The company partners with Elanco Animal Health to facilitate the distribution of TANOVEA®, ensuring veterinary practices can access this specialized treatment. Revenue is established via direct purchases by veterinary clinics tailored to their patients' needs, creating a consistent revenue stream from TANOVEA® sales. The treatment is positioned as a premium offering within the veterinary oncology market, reflective of its specialized development.VetDC intends to expand its product line by developing new innovative treatments for veterinary cancer care. Strategies for market expansion include targeting additional regions within Europe and Asia by 2025, leveraging recent funding to support these initiatives. The USD 2.5 million raised in Series A financing will significantly contribute to research and development, allowing VetDC to enhance its product offerings and market reach.

## Funding rounds

- Series A, Nov 24, 2014, $2.5M — High Country Venture

## Investors

- High Country Venture (https://capitalatlas.ai/funds/high-country-venture) — Series A